Explanation for failure of TMC-125 (etravirine) in TMC227 study
6 December 2006. Related: Conference reports, Antiretrovirals.
Conference reports
Saquinavir/r vs lopinavir/r: interim results from the Gemini study
6 December 2006. Related: Conference reports, Antiretrovirals.
d4T associated with significantly increased risk of type-2 diabetes mellitus
6 December 2006. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Drug interactions with darunavir (TMC-114)
6 December 2006. Related: Conference reports, PK and drug interactions.
Drug interactions with etravirine (TMC-125)
6 December 2006. Related: Conference reports, PK and drug interactions.
Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia
6 December 2006. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Community meeting on criminalisation of HIV transmission: jailing people for passing on HIV may threaten public health
6 December 2006. Related: Conference reports.
8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 23-26 September 2006, San Francisco
16 October 2006. Related: Conference reports.
The role of the metabolic syndrome in HIV
15 October 2006. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome
9 October 2006. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat
9 October 2006. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
Leptin reduces visceral abdominal tissue (VAT) without reducing limb fat
8 October 2006. Related: Conference reports.
Adipose tissue morphology improved after treatment discontinuation
8 October 2006. Related: Conference reports.
Incidence of lipodystrophy in Rwanda
8 October 2006. Related: Conference reports.
46th Interscience Conference on Antiretroviral Agents and Chemotherapy (ICAAC), 27-30 September 2006, San Francisco
7 October 2006. Related: Conference reports.
MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results
7 October 2006. Related: Conference reports, Drug resistance.
Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients
7 October 2006. Related: Conference reports, Antiretrovirals.
Cell studies predict cross-resistance among integrase inhibitors
7 October 2006. Related: Conference reports, Drug resistance.
HIV may use different coreceptors in blood and brain
7 October 2006. Related: Conference reports, Basic science and immunology.
Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives
7 October 2006. Related: Conference reports, PK and drug interactions.
NRTI elvucitabine active against HIV in a 7-day monotherapy study
7 October 2006. Related: Conference reports, Antiretrovirals.
Efavirenz/tenofovir fails as 2-drug maintenance regimen
7 October 2006. Related: Conference reports, Antiretrovirals.
Nucleoside inhibitor MK-0608 mediates suppression of HCV replication for >30 days in chronically infected chimpanzees
7 October 2006. Related: Conference reports, Hepatitis coinfection.
Report from the 10th Annual UK Resistance Meeting, 21 September 2006, London
7 October 2006. Related: Conference reports, Drug resistance.
Further reports from XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada
7 October 2006. Related: Conference reports.
Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV positive women in Lusaka, Zambia
7 October 2006. Related: Conference reports, Women's health, Cancer and HIV.
Effect of herpes simplex therapy on genital and plasma HIV viral load
7 October 2006. Related: Conference reports, Women's health.
Maternal health and prevention of mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
18-month effectiveness of short-course perinatal antiretroviral regimens combined to infant-feeding interventions for PMTCT in DITRAME PLUS ANRS 1201/1202 2001-2005
7 October 2006. Related: Conference reports, Pregnancy.
HIV prevalence rates amongst 6 week old infants in South Africa: the case for universal screening at immunisation clinics
7 October 2006. Related: Conference reports, Pregnancy.
Maternal illness during pregnancy is associated with In utero mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
Extensively drug resistant TB (XTB) in South Africa
7 October 2006. Related: Conference reports, TB coinfection.
XVI International AIDS Conference, Toronto, Canada. 13-18 August 2006
15 September 2006. Related: Conference reports.
Enough is enough: South African activists demand: fire Manto
10 September 2006. Related: Conference reports, Treatment access.
Treatment access: more optimistic results from scale up programmes
10 September 2006. Related: Conference reports, Treatment access.
Integrase inhibitor MK-0518: early results show greater early potency than efavirenz
10 September 2006. Related: Conference reports, Antiretrovirals.
Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect
10 September 2006. Related: Conference reports, Antiretrovirals.
Vicriviroc 24-week results in triple-class experienced R5-tropic patients
10 September 2006. Related: Conference reports, Antiretrovirals.
Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355
9 September 2006. Related: Conference reports, Antiretrovirals.
New data on darunavir (TMC-114)
9 September 2006. Related: Conference reports, Antiretrovirals.
Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance
9 September 2006. Related: Conference reports, Antiretrovirals.
Atazanavir/r monotherapy and CNS penetration
9 September 2006. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks
9 September 2006. Related: Conference reports, Antiretrovirals.
Children face a serious service delivery gap: paediatric studies in Toronto
9 September 2006. Related: Conference reports, Paediatric care.
Bioavailability study results for new paediatric tablets for oral suspension, and caution against splitting adult doses
9 September 2006. Related: Conference reports, Paediatric care.
Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) Trial
9 September 2006. Related: Conference reports, Paediatric care.
3TC/abacavir maintains virological superiority over AZT/3TC and AZT/abacavir beyond 5 years in children
9 September 2006. Related: Conference reports, Paediatric care.
French study raises importance of early screening for anal cancer in HIV-positive people
9 September 2006. Related: Conference reports, Coinfections and complications, Cancer and HIV.
Prognostic index for risk of progression of Kaposis Sarcoma
9 September 2006. Related: Conference reports, Coinfections and complications.
Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin
9 September 2006. Related: Conference reports, Side effects, Cancer and HIV.
Selected abstracts from Track A presentations at Toronto
9 September 2006. Related: Conference reports, Basic science and immunology.
Use of complementary alternative medicine that could interact with ARV treatment reported by 20% patients in the UK
9 September 2006. Related: Conference reports.
Poor scientific or medical knowledge is a factor in increase in criminal charges for HIV transmission in the UK
9 September 2006. Related: Conference reports.
Treatment access and community responses: online webcasts and debates
9 September 2006. Related: Conference reports, Treatment access.
15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain
3 August 2006. Related: Conference reports, Drug resistance.
Resistance implications of monotherapy with lopinavir/r (Kaletra)
3 August 2006. Related: Conference reports, Drug resistance.
Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir
3 August 2006. Related: Conference reports, Drug resistance.
Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients
3 August 2006. Related: Conference reports, Drug resistance.
Epidemiological studies and transmission of resistance: evidence for optimism or issues with interpretation?
3 August 2006. Related: Conference reports, HIV prevention and transmission, Drug resistance.
K103N containing variants persist longer in women with subtype D and with higher viral loads
3 August 2006. Related: Conference reports, Drug resistance.
No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine
3 August 2006. Related: Conference reports, Drug resistance.
Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women
3 August 2006. Related: Conference reports, Drug resistance.
High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens
3 August 2006. Related: Conference reports, Drug resistance.